c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma
Objectives In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patient...
Uložené v:
| Vydané v: | European journal of haematology Ročník 105; číslo 1; s. 35 - 46 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Wiley Subscription Services, Inc
01.07.2020
John Wiley and Sons Inc |
| Predmet: | |
| ISSN: | 0902-4441, 1600-0609, 1600-0609 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Objectives
In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT).
Methods
RNA sequencing data were used to investigate the basis of these differences.
Results
The PFS benefit of IRd vs placebo‐Rd was greater in patients with tumors expressing high c‐MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c‐MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c‐MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81.
Conclusions
PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c‐MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE‐MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537 |
|---|---|
| AbstractList | ObjectivesIn the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT).MethodsRNA sequencing data were used to investigate the basis of these differences.ResultsThe PFS benefit of IRd vs placebo‐Rd was greater in patients with tumors expressing high c‐MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c‐MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c‐MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81.ConclusionsPFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c‐MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE‐MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537 In the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of progression-free survival (PFS) benefit vs placebo-Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT).OBJECTIVESIn the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of progression-free survival (PFS) benefit vs placebo-Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT).RNA sequencing data were used to investigate the basis of these differences.METHODSRNA sequencing data were used to investigate the basis of these differences.The PFS benefit of IRd vs placebo-Rd was greater in patients with tumors expressing high c-MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c-MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c-MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81.RESULTSThe PFS benefit of IRd vs placebo-Rd was greater in patients with tumors expressing high c-MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c-MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c-MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81.PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE-MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537.CONCLUSIONSPFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE-MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537. Objectives In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT). Methods RNA sequencing data were used to investigate the basis of these differences. Results The PFS benefit of IRd vs placebo‐Rd was greater in patients with tumors expressing high c‐MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c‐MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c‐MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81. Conclusions PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c‐MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE‐MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537 In the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of progression-free survival (PFS) benefit vs placebo-Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT). RNA sequencing data were used to investigate the basis of these differences. The PFS benefit of IRd vs placebo-Rd was greater in patients with tumors expressing high c-MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c-MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c-MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81. PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOURMALINE-MM1 study. This trial was registered at www.clinicaltrials.gov as: NCT01564537. |
| Author | Zhang, Jacob Keats, Jonathan J. Cavo, Michele Lin, Jianchang Moreau, Philippe Langer, Christian Richardson, Paul G. Rajkumar, S. Vincent Munshi, Nikhil C. Shen, Lei Badola, Sunita Viterbo, Luísa Li, Bin Avet‐Loiseau, Hervé Velde, Helgi Esseltine, Dixie‐Lee Kumar, Shaji K. Berg, Deborah Ganly, Peter Di Bacco, Alessandra Masszi, Tamás Pour, Ludek Bahlis, Nizar J. Luptakova, Katarina |
| AuthorAffiliation | 1 Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) Cambridge MA USA 8 Hematology and Oncology University Hospital Brno Brno Czech Republic 3 Hematologic Oncology Dana‐Farber Cancer Institute Boston MA USA 7 Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE) Porto Portugal 4 Hematology IUC‐Oncopole Toulouse France 12 Division of Hematology Mayo Clinic Rochester MN USA 6 3rd Department of Internal Medicine Semmelweis University Budapest Hungary 2 Southern Alberta Cancer Research Institute University of Calgary Calgary AB Canada 9 Department of Haematology Christchurch Hospital Christchurch New Zealand 5 Department of Haematology and Stem Cell Transplantation St. István and St. László Hospital of Budapest Budapest Hungary 11 University Hospital of Ulm Ulm Germany 14 Department of Hematology University Hospital Hôtel Dieu University of Nantes Nantes France 13 Translational Genomics Research Institu |
| AuthorAffiliation_xml | – name: 9 Department of Haematology Christchurch Hospital Christchurch New Zealand – name: 7 Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE) Porto Portugal – name: 11 University Hospital of Ulm Ulm Germany – name: 6 3rd Department of Internal Medicine Semmelweis University Budapest Hungary – name: 13 Translational Genomics Research Institute (TGEN) Phoenix AZ USA – name: 8 Hematology and Oncology University Hospital Brno Brno Czech Republic – name: 12 Division of Hematology Mayo Clinic Rochester MN USA – name: 5 Department of Haematology and Stem Cell Transplantation St. István and St. László Hospital of Budapest Budapest Hungary – name: 1 Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) Cambridge MA USA – name: 2 Southern Alberta Cancer Research Institute University of Calgary Calgary AB Canada – name: 10 Institute of Hematology and Medical Oncology "Seràgnoli" Bologna University School of Medicine S.Orsola's University Hospital Bologna Italy – name: 3 Hematologic Oncology Dana‐Farber Cancer Institute Boston MA USA – name: 14 Department of Hematology University Hospital Hôtel Dieu University of Nantes Nantes France – name: 4 Hematology IUC‐Oncopole Toulouse France |
| Author_xml | – sequence: 1 givenname: Alessandra orcidid: 0000-0003-2072-8712 surname: Di Bacco fullname: Di Bacco, Alessandra email: Alessandra.DiBacco@Takeda.com organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 2 givenname: Nizar J. surname: Bahlis fullname: Bahlis, Nizar J. organization: University of Calgary – sequence: 3 givenname: Nikhil C. surname: Munshi fullname: Munshi, Nikhil C. organization: Dana‐Farber Cancer Institute – sequence: 4 givenname: Hervé surname: Avet‐Loiseau fullname: Avet‐Loiseau, Hervé organization: IUC‐Oncopole – sequence: 5 givenname: Tamás surname: Masszi fullname: Masszi, Tamás organization: Semmelweis University – sequence: 6 givenname: Luísa surname: Viterbo fullname: Viterbo, Luísa organization: Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE) – sequence: 7 givenname: Ludek surname: Pour fullname: Pour, Ludek organization: University Hospital Brno – sequence: 8 givenname: Peter surname: Ganly fullname: Ganly, Peter organization: Christchurch Hospital – sequence: 9 givenname: Michele surname: Cavo fullname: Cavo, Michele organization: S.Orsola's University Hospital – sequence: 10 givenname: Christian surname: Langer fullname: Langer, Christian organization: University Hospital of Ulm – sequence: 11 givenname: Shaji K. surname: Kumar fullname: Kumar, Shaji K. organization: Mayo Clinic – sequence: 12 givenname: S. Vincent surname: Rajkumar fullname: Rajkumar, S. Vincent organization: Mayo Clinic – sequence: 13 givenname: Jonathan J. surname: Keats fullname: Keats, Jonathan J. organization: Translational Genomics Research Institute (TGEN) – sequence: 14 givenname: Deborah surname: Berg fullname: Berg, Deborah organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 15 givenname: Jianchang surname: Lin fullname: Lin, Jianchang organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 16 givenname: Bin surname: Li fullname: Li, Bin organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 17 givenname: Sunita surname: Badola fullname: Badola, Sunita organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 18 givenname: Lei surname: Shen fullname: Shen, Lei organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 19 givenname: Jacob surname: Zhang fullname: Zhang, Jacob organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 20 givenname: Dixie‐Lee surname: Esseltine fullname: Esseltine, Dixie‐Lee organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 21 givenname: Katarina surname: Luptakova fullname: Luptakova, Katarina organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 22 givenname: Helgi surname: Velde fullname: Velde, Helgi organization: Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) – sequence: 23 givenname: Paul G. surname: Richardson fullname: Richardson, Paul G. organization: Dana‐Farber Cancer Institute – sequence: 24 givenname: Philippe orcidid: 0000-0003-1780-8746 surname: Moreau fullname: Moreau, Philippe organization: University of Nantes |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32145111$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ksFu1DAQhi1URLeFAy-ALHGBQ1o7ceLNBQmtCgUVcYALJ2sST4hXib3YDt1w4hGQeEOeBC-7RVCBL5bl___8z3hOyJF1Fgl5yNkZT-sc1_0ZLwQr75AFrxjLWMXqI7JgNcszIQQ_JichrBljec3lPXJc5FyUybkg39sfX7-9-bCiuN14DME4S8FqOkKcvIkz3fRoXZw3GCh4pBCCaw1E1PTaxJ66KbZuRNqgxc5E2nk3UtDaxB3JddRs4YsbTUOjowNaGIxOR43pWY1bGDH2EFI51Fg6zji4Ee6Tux0MAR8c9lPy7sXF-9VldvX25avV86usFaIos6IVS13WIJuuhmXDZAWprq6rdFfjstG8AuBalk0lRF4JXbYVr4tcLhnHihWn5NmeupmaEXWLNnoY1MabEfysHBj19401vfroPitZcClZmQBPDgDvPk0YohpNaHEYwKKbgsoLKQpRyVIk6eNb0rWbfGpGUgleyKXI5Q746M9Ev6Pc_FYSnO8FrXcheOxUayLsOp0CmkFxpnbzoNI8qF_zkBxPbzluoP_SHujXZsD5_0J18fpy7_gJJJXJlg |
| CitedBy_id | crossref_primary_10_1016_j_jtct_2022_11_005 crossref_primary_10_3390_biom15050702 crossref_primary_10_1111_ejh_13435 crossref_primary_10_3390_cancers13194867 crossref_primary_10_1002_1878_0261_12835 crossref_primary_10_3390_life13112229 |
| Cites_doi | 10.1182/blood-2007-07-104422 10.1038/bmt.2015.307 10.1158/1078-0432.CCR-05-0523 10.1038/nm1763 10.1038/bmt.2013.150 10.1158/0008-5472.CAN-15-2477 10.1182/blood.V96.13.4357 10.1016/j.celrep.2019.06.029 10.3324/haematol.2017.170118 10.1038/bmt.2008.166 10.3324/haematol.2015.136929 10.18632/oncotarget.17630 10.1016/j.ccr.2013.08.009 10.1038/nrclinonc.2016.122 10.3109/10428194.2010.531409 10.1111/bjh.12563 10.1002/eji.200737743 10.1128/MCB.19.1.1 10.1126/science.276.5312.596 10.1016/j.bbrc.2012.03.056 10.1186/1471-2164-10-323 10.1038/modpathol.3800169 10.1016/S0889-8588(18)30346-0 10.1016/j.yexcr.2010.03.013 10.1101/cshperspect.a014217 10.1038/bmt.2014.237 10.1056/NEJMoa1504542 10.1038/bcj.2014.13 10.1007/s10875-015-0148-2 10.18632/oncotarget.8581 10.1111/j.1600-0609.2009.01277.x 10.1101/gad.313104 10.3324/haematol.2017.186601 10.1056/NEJMoa1516282 10.1038/sj.emboj.7601009 10.1080/10428194.2016.1187275 10.1038/s41375-018-0036-x 10.1038/nrc746 10.1182/blood-2006-08-040410 10.1093/nar/gku763 10.1182/blood-2010-02-270082 10.1038/ni1201-1103 10.1038/nature12213 10.1182/blood-2012-01-405985 10.3109/10428194.2014.924116 10.1172/JCI61188 10.1155/2014/232546 10.1038/leu.2011.53 10.1016/j.clml.2014.06.011 |
| ContentType | Journal Article |
| Copyright | 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Published by John Wiley & Sons Ltd 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited European Journal of Haematology Published by John Wiley & Sons Ltd. 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Published by John Wiley & Sons Ltd – notice: 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited European Journal of Haematology Published by John Wiley & Sons Ltd. – notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 7QG 7T5 7TM 7TO H94 K9. 7X8 5PM |
| DOI | 10.1111/ejh.13405 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed Animal Behavior Abstracts Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Oncogenes and Growth Factors Abstracts Animal Behavior Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | DI BACCO et al |
| EISSN | 1600-0609 |
| EndPage | 46 |
| ExternalDocumentID | PMC7317705 32145111 10_1111_ejh_13405 EJH13405 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQQT AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EGARE EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 Y6R YFH YUY ZCG ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X NPM 7QG 7T5 7TM 7TO H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c4435-3c48d59a7bf9a8b076a321ff6df9e8bd16aa1d75b644264d5c619327801e603 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000526165700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0902-4441 1600-0609 |
| IngestDate | Tue Nov 04 01:58:39 EST 2025 Sun Nov 09 10:20:43 EST 2025 Tue Oct 07 07:03:21 EDT 2025 Wed Feb 19 02:31:08 EST 2025 Tue Nov 18 21:45:36 EST 2025 Sat Nov 29 06:55:15 EST 2025 Wed Jan 22 16:33:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | RNA sequencing mutation c-myc Proto-Oncogenes multiple myeloma progression-free survival |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited European Journal of Haematology Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4435-3c48d59a7bf9a8b076a321ff6df9e8bd16aa1d75b644264d5c619327801e603 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Affiliation at the time that the work was conducted: Katarina Luptakova, Tesaro, Waltham, MA, USA; Helgi van de Velde, Sanofi, Cambridge, MA, USA. |
| ORCID | 0000-0003-1780-8746 0000-0003-2072-8712 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fejh.13405 |
| PMID | 32145111 |
| PQID | 2413784275 |
| PQPubID | 2045159 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7317705 proquest_miscellaneous_2374346754 proquest_journals_2413784275 pubmed_primary_32145111 crossref_citationtrail_10_1111_ejh_13405 crossref_primary_10_1111_ejh_13405 wiley_primary_10_1111_ejh_13405_EJH13405 |
| PublicationCentury | 2000 |
| PublicationDate | July 2020 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: July 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | European journal of haematology |
| PublicationTitleAlternate | Eur J Haematol |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2015; 35 2017; 8 2012; 120 2013; 3 2012; 122 2013; 24 2009; 83 1997; 276 2008; 38 2016; 76 2016; 101 2011; 52 2013; 163 2007; 109 1992; 6 2014; 4 2009; 10 2010; 316 1999; 19 2010; 115 2000; 96 2006; 25 2015; 373 2019; 28 2014; 14 2011; 25 2008; 111 2018; 32 2015; 56 2012; 420 2015; 50 2018; 103 2014; 49 2008; 14 2002; 2 2016; 51 2014; 2014 2016; 57 2014; 42 2016; 7 2004; 18 2017; 14 2004; 17 2013; 499 2016; 374 2001; 2 2008; 42 2017; 102 2005; 11 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_42_1 e_1_2_10_40_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_32_1 e_1_2_10_30_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_24_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_28_1 e_1_2_10_49_1 e_1_2_10_26_1 e_1_2_10_47_1 |
| References_xml | – volume: 18 start-page: 2747 issue: 22 year: 2004 end-page: 2763 article-title: c‐Myc controls the balance between hematopoietic stem cell self‐renewal and differentiation publication-title: Genes Dev – volume: 28 start-page: 472 issue: 2 year: 2019 end-page: 485 article-title: MTA2/NuRD Regulates B Cell Development and Cooperates with OCA‐B in Controlling the Pre‐B to Immature B Cell Transition publication-title: Cell Rep – volume: 103 start-page: e368 issue: 8 year: 2018 end-page: e371 article-title: Cereblon loss and up‐regulation of c‐Myc are associated with lenalidomide resistance in multiple myeloma patients publication-title: Haematologica – volume: 76 start-page: 3319 issue: 11 year: 2016 end-page: 3331 article-title: Proteasomal inhibition by ixazomib induces CHK1 and MYC‐dependent cell death in T‐cell and Hodgkin lymphoma publication-title: Cancer Res – volume: 316 start-page: 1816 issue: 11 year: 2010 end-page: 1828 article-title: Bone marrow stromal cell interaction reduces syndecan‐1 expression and induces kinomic changes in myeloma cells publication-title: Exp Cell Res – volume: 499 start-page: 214 issue: 7457 year: 2013 end-page: 218 article-title: Mutational heterogeneity in cancer and the search for new cancer‐associated genes publication-title: Nature – volume: 3 start-page: a014217 issue: 8 year: 2013 article-title: MYC metabolism, cell growth, and tumorigenesis publication-title: Cold Spring Harb Perspect Med – volume: 24 start-page: 289 issue: 3 year: 2013 end-page: 304 article-title: Xbp1s‐negative tumor B cells and pre‐plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma publication-title: Cancer Cell – volume: 420 start-page: 644 issue: 3 year: 2012 end-page: 650 article-title: Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma publication-title: Biochem Biophys Res Commun – volume: 52 start-page: 34 issue: 1 year: 2011 end-page: 41 article-title: Novel agents improve survival of transplant patients with multiple myeloma including those with high‐risk disease defined by early relapse (<12 months) publication-title: Leuk Lymphoma – volume: 50 start-page: 204 issue: 2 year: 2015 end-page: 208 article-title: Early relapse after single auto‐SCT for multiple myeloma is a major predictor of survival in the era of novel agents publication-title: Bone Marrow Transplant – volume: 2 start-page: 1103 issue: 12 year: 2001 end-page: 1108 article-title: Plasma cells: finding new light at the end of B cell development publication-title: Nat Immunol – volume: 25 start-page: 1104 issue: 5 year: 2006 end-page: 1113 article-title: Progressively impaired proteasomal capacity during terminal plasma cell differentiation publication-title: EMBO J – volume: 35 start-page: 254 issue: 3 year: 2015 end-page: 263 article-title: A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression publication-title: J Clin Immunol – volume: 373 start-page: 1040 issue: 11 year: 2015 end-page: 1047 article-title: Chimeric antigen receptor T cells against CD19 for multiple myeloma publication-title: N Engl J Med – volume: 4 start-page: e191 year: 2014 article-title: Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients publication-title: Blood Cancer J – volume: 6 start-page: 297 issue: 2 year: 1992 end-page: 322 article-title: Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules publication-title: Hematol Oncol Clin North Am – volume: 122 start-page: 3456 issue: 10 year: 2012 end-page: 3463 article-title: Molecular pathogenesis of multiple myeloma and its premalignant precursor publication-title: J Clin Invest – volume: 42 start-page: 10433 issue: 16 year: 2014 end-page: 10447 article-title: MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib publication-title: Nucleic Acids Res – volume: 57 start-page: 2526 issue: 11 year: 2016 end-page: 2534 article-title: Overexpression of c‐myc is associated with adverse clinical features and worse overall survival in multiple myeloma publication-title: Leuk Lymphoma – volume: 25 start-page: 1026 issue: 6 year: 2011 end-page: 1035 article-title: Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma publication-title: Leukemia – volume: 11 start-page: 7599 issue: 21 year: 2005 end-page: 7606 article-title: The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis‐resistant phenotype publication-title: Clin Cancer Res – volume: 7 start-page: 28096 issue: 19 year: 2016 end-page: 28111 article-title: Differential effects of lenalidomide during plasma cell differentiation publication-title: Oncotarget – volume: 115 start-page: 3772 issue: 18 year: 2010 end-page: 3775 article-title: A proto‐oncogene BCL6 is up‐regulated in the bone marrow microenvironment in multiple myeloma cells publication-title: Blood – volume: 374 start-page: 1621 issue: 17 year: 2016 end-page: 1634 article-title: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med – volume: 120 start-page: 1067 issue: 5 year: 2012 end-page: 1076 article-title: Clonal competition with alternating dominance in multiple myeloma publication-title: Blood – volume: 276 start-page: 596 issue: 5312 year: 1997 end-page: 599 article-title: Repression of c‐myc transcription by Blimp‐1, an inducer of terminal B cell differentiation publication-title: Science – volume: 102 start-page: 1767 issue: 10 year: 2017 end-page: 1775 article-title: Impact of prior therapy on the efficacy and safety of oral ixazomib‐lenalidomide‐dexamethasone vs. placebo‐lenalidomide‐dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE‐MM1 publication-title: Haematologica – volume: 14 start-page: 100 issue: 2 year: 2017 end-page: 113 article-title: Genomic complexity of multiple myeloma and its clinical implications publication-title: Nat Rev Clin Oncol – volume: 96 start-page: 4357 issue: 13 year: 2000 end-page: 4359 article-title: Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma publication-title: Blood – volume: 109 start-page: 3489 issue: 8 year: 2007 end-page: 3495 article-title: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome publication-title: Blood – volume: 8 start-page: 56338 issue: 34 year: 2017 end-page: 56350 article-title: Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing publication-title: Oncotarget – volume: 51 start-page: 479 issue: 4 year: 2016 end-page: 491 article-title: Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity publication-title: Bone Marrow Transplant – volume: 19 start-page: 1 issue: 1 year: 1999 end-page: 11 article-title: c‐Myc target genes involved in cell growth, apoptosis, and metabolism publication-title: Mol Cell Biol – volume: 10 start-page: 323 year: 2009 article-title: A Myc‐regulated transcriptional network controls B‐cell fate in response to BCR triggering publication-title: BMC Genomics – volume: 163 start-page: 551 issue: 5 year: 2013 end-page: 564 article-title: Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma publication-title: Br J Haematol – volume: 17 start-page: 1217 issue: 10 year: 2004 end-page: 1222 article-title: Expression of PAX5 in CD20‐positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray publication-title: Mod Pathol – volume: 38 start-page: 658 issue: 3 year: 2008 end-page: 667 article-title: Dampening Ab responses using proteasome inhibitors following in vivo B cell activation publication-title: Eur J Immunol – volume: 49 start-page: 223 issue: 2 year: 2014 end-page: 227 article-title: Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma publication-title: Bone Marrow Transplant – volume: 2014 start-page: 1 year: 2014 end-page: 12 article-title: Implications of heterogeneity in multiple myeloma publication-title: Biomed Res Int – volume: 101 start-page: e116 issue: 3 year: 2016 end-page: e119 article-title: Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma publication-title: Haematologica – volume: 56 start-page: 602 issue: 3 year: 2015 end-page: 607 article-title: Chromosome 8q24.1/c‐MYC abnormality: a marker for high‐risk myeloma publication-title: Leuk Lymphoma – volume: 83 start-page: 191 issue: 3 year: 2009 end-page: 202 article-title: All‐trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells publication-title: Eur J Haematol – volume: 111 start-page: 1543 issue: 3 year: 2008 end-page: 1551 article-title: Cbfbeta‐SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B‐cell development publication-title: Blood – volume: 14 start-page: 748 issue: 7 year: 2008 end-page: 755 article-title: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus‐like disease from nephritis publication-title: Nat Med – volume: 42 start-page: 259 issue: 4 year: 2008 end-page: 264 article-title: Impact of additional cytoreduction following autologous SCT in multiple myeloma publication-title: Bone Marrow Transplant – volume: 14 start-page: S65 issue: Suppl year: 2014 end-page: S70 article-title: Biology and treatment of myeloma publication-title: Clin Lymphoma Myeloma Leuk – volume: 32 start-page: 1295 issue: 6 year: 2018 end-page: 1306 article-title: Targeting MYC in multiple myeloma publication-title: Leukemia – volume: 2 start-page: 175 issue: 3 year: 2002 end-page: 187 article-title: Multiple myeloma: evolving genetic events and host interactions publication-title: Nat Rev Cancer – ident: e_1_2_10_34_1 doi: 10.1182/blood-2007-07-104422 – ident: e_1_2_10_6_1 doi: 10.1038/bmt.2015.307 – ident: e_1_2_10_40_1 doi: 10.1158/1078-0432.CCR-05-0523 – ident: e_1_2_10_50_1 doi: 10.1038/nm1763 – ident: e_1_2_10_32_1 doi: 10.1038/bmt.2013.150 – ident: e_1_2_10_25_1 doi: 10.1158/0008-5472.CAN-15-2477 – ident: e_1_2_10_39_1 doi: 10.1182/blood.V96.13.4357 – ident: e_1_2_10_35_1 doi: 10.1016/j.celrep.2019.06.029 – ident: e_1_2_10_8_1 doi: 10.3324/haematol.2017.170118 – ident: e_1_2_10_30_1 doi: 10.1038/bmt.2008.166 – ident: e_1_2_10_18_1 doi: 10.3324/haematol.2015.136929 – ident: e_1_2_10_5_1 doi: 10.18632/oncotarget.17630 – ident: e_1_2_10_46_1 doi: 10.1016/j.ccr.2013.08.009 – ident: e_1_2_10_3_1 doi: 10.1038/nrclinonc.2016.122 – ident: e_1_2_10_31_1 doi: 10.3109/10428194.2010.531409 – ident: e_1_2_10_36_1 doi: 10.1111/bjh.12563 – ident: e_1_2_10_49_1 doi: 10.1002/eji.200737743 – ident: e_1_2_10_22_1 doi: 10.1128/MCB.19.1.1 – ident: e_1_2_10_23_1 doi: 10.1126/science.276.5312.596 – ident: e_1_2_10_44_1 doi: 10.1016/j.bbrc.2012.03.056 – ident: e_1_2_10_24_1 doi: 10.1186/1471-2164-10-323 – ident: e_1_2_10_33_1 doi: 10.1038/modpathol.3800169 – ident: e_1_2_10_38_1 doi: 10.1016/S0889-8588(18)30346-0 – ident: e_1_2_10_41_1 doi: 10.1016/j.yexcr.2010.03.013 – ident: e_1_2_10_9_1 doi: 10.1101/cshperspect.a014217 – ident: e_1_2_10_29_1 doi: 10.1038/bmt.2014.237 – ident: e_1_2_10_37_1 doi: 10.1056/NEJMoa1504542 – ident: e_1_2_10_17_1 doi: 10.1038/bcj.2014.13 – ident: e_1_2_10_14_1 doi: 10.1007/s10875-015-0148-2 – ident: e_1_2_10_45_1 doi: 10.18632/oncotarget.8581 – ident: e_1_2_10_47_1 doi: 10.1111/j.1600-0609.2009.01277.x – ident: e_1_2_10_13_1 doi: 10.1101/gad.313104 – ident: e_1_2_10_28_1 doi: 10.3324/haematol.2017.186601 – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa1516282 – ident: e_1_2_10_48_1 doi: 10.1038/sj.emboj.7601009 – ident: e_1_2_10_27_1 doi: 10.1080/10428194.2016.1187275 – ident: e_1_2_10_20_1 doi: 10.1038/s41375-018-0036-x – ident: e_1_2_10_21_1 doi: 10.1038/nrc746 – ident: e_1_2_10_15_1 doi: 10.1182/blood-2006-08-040410 – ident: e_1_2_10_26_1 doi: 10.1093/nar/gku763 – ident: e_1_2_10_42_1 doi: 10.1182/blood-2010-02-270082 – ident: e_1_2_10_43_1 doi: 10.1038/ni1201-1103 – ident: e_1_2_10_2_1 doi: 10.1038/nature12213 – ident: e_1_2_10_16_1 doi: 10.1182/blood-2012-01-405985 – ident: e_1_2_10_11_1 doi: 10.3109/10428194.2014.924116 – ident: e_1_2_10_10_1 doi: 10.1172/JCI61188 – ident: e_1_2_10_4_1 doi: 10.1155/2014/232546 – ident: e_1_2_10_12_1 doi: 10.1038/leu.2011.53 – ident: e_1_2_10_19_1 doi: 10.1016/j.clml.2014.06.011 |
| SSID | ssj0002917 |
| Score | 2.3127449 |
| Snippet | Objectives
In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes... In the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of... ObjectivesIn the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 35 |
| SubjectTerms | CD19 antigen CD81 antigen c‐myc Proto‐Oncogenes Dexamethasone Immunotherapy Multiple myeloma mutation Myc protein Original Phenotypes progression‐free survival Ribonucleic acid RNA RNA sequencing Stem cell transplantation Targeted cancer therapy Tumors |
| Title | c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fejh.13405 https://www.ncbi.nlm.nih.gov/pubmed/32145111 https://www.proquest.com/docview/2413784275 https://www.proquest.com/docview/2374346754 https://pubmed.ncbi.nlm.nih.gov/PMC7317705 |
| Volume | 105 |
| WOSCitedRecordID | wos000526165700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1600-0609 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002917 issn: 0902-4441 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEBYhKaWX_jfdNA3T0kMuLmtLtmR6KmmWUJIQ-gPbk5Esibhk7bLrDdue-giFvmGfpDNar8mSFgq9GBuN0aDRaD5L428Ye8EdBjlleJQJk0ZCeR1pxUXEfeodeljmfbD0sTw9VeNxfrbBXq3-hVnyQ_QbbuQZYb0mB9dmdsXJ3efzlzEXxF-6FcdcUd2GRJz1y3CSh3K7lHcYCQz6Ha0QpfH0r64Ho2sI83qi5FUAGyLQ6M5_6X6X3e6AJ7xezpR7bMPV99nNk-5o_QH7Wf76_uPk0wG4RZcbW4OuLUyI-ROhOlAyWEM7tjPQUwe6s6uzQHu50Mxb1MKBwcXTVy3QfytA2UpkeWg8VAv9rZlUBtoGMNQh_rf4aB12a91CUylrjeDfQVXD5Ku7aCb6IXs_OvxwcBR1FRuiUiDuingplE1zLY3PtTJDmWmexGhu63OnjI0zrWMrU4MoDJGYTcuMAKTEMOmyIX_ENmvs5zGDuDSlGXpZEkMg8RdwL9OSZ8pKNKuwA7a_MlxRdmTmVFPjolh91OAQF2GIB-x5L_plyeDxJ6HdlfWLzolnBR05SiUSic3P-mZ0PzpT0bVr5ijDEYJhsEnFgG0vJ0vfC9WAQjwbD5hcm0a9AFF7r7fU1Xmg-JYI6ySptR-m0d8VLw7fHoWbnX8XfcJuJbRrEJKOd9lmO527p-xGedlWs-le8CK8yrHaY1tv3o0-Hv8GOAwnRw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEF9KFfXFb-1p1VF86EvKJbvJJuCLlJZT746CfahPYT9ppJeU-5DTJ_8Ewf_Qv8SZvVzoUQXBt4SdsEtmZueX2clvGHvNHQa5XPMoEzqNRO5VpHIuIu5T79DDMu-DpodyPM5PT4vjLfZm_S_Mih-iS7iRZ4T9mhycEtKXvNx9PtuPuSAC02sCowxZeSKOu304KUK_XSo8jARG_ZZXiOp4ukc3o9EViHm1UvIygg0h6OjO_y3-LrvdQk94u7KVe2zL1ffZjVF7uP6A_TS_vv8YfToAt2yrY2tQtYUJcX8iWAcqB2soZzsDNXWgWs06C5TNhWYxx2U40Lh9-moO9OcKUL0S6R4aD9VSfWsmlYZ5Axjs8AvA4q11OK11S0XNrBXCfwdVDZOv7ryZqIfs49HhycEgans2REYg8oq4EblNCyW1L1Su-zJTPIlR4dYXLtc2zpSKrUw14jDEYjY1GUFIiYHSZX3-iG3XOM8Og9hoo_teGuIIJAYD7mVqeJZbiXoVtsf21porTUtnTl01zsv1Zw2-4jK84h571YlerDg8_iS0u1Z_2brxrKRDR5mLROLwy24YHZBOVVTtmgXKcARhGG5S0WOPV9bSzUJdoBDRxj0mN-yoEyBy782RujoLJN8SgZ2kZe0FO_r7wsvD94Nw8eTfRV-wm4OT0bAcvht_eMpuJZRDCCXIu2x7Pl24Z-y6-TKvZtPnwaV-A381KKo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEF6CU0IvSd9xmrbT0kMuKpZ3pZWgl5LEpK1jQh-QnsQ-iUosBVsubk_9CYH8w_6SzsiyiEkLhd4kdsQuOzs7386OvmHsJXfo5BLNg1joKBCJV4FKuAi4j7xDC4u9rzU9lKNRcnqanqyx18t_YRb8EG3AjSyj3q_JwN2F9des3H09exVyQQSm64KKyHTY-sGHwedhuxP307riLqUeBgL9fsMsRJk87cer_ugGyLyZK3kdw9ZOaLD1f8O_wzYb8AlvFqvlLltzxT22cdxcr99nV-bXz8vjL_vg5k1-bAGqsDAm9k-E60AJYSVFbaegJg5Uo1tngeK5UM4qHIYDjRuozyugf1eAMpZI-1B6yOfqRznONVQloLvDM4DFV-uwW-vmispZKzwAOMgLGH935-VYPWAfB4ef9o-CpmpDYARir4AbkdgoVVL7VCW6J2PF-yGq3PrUJdqGsVKhlZFGJIZozEYmJhAp0VW6uMcfsk6B_WwzCI02uuelIZZA4jDgXkaGx4mVqFdhu2xvqbnMNITmVFfjPFsebHCKs3qKu-xFK3qxYPH4k9DuUv1ZY8jTjK4dZSL6Epuft81ognSvogpXzlCGIwxDhxOJLnu0WC1tL1QHCjFt2GVyZR21AkTvvdpS5Gc1zbdEaCdpWHv1Ovr7wLPDd0f1w86_iz5jGycHg2z4dvT-MbvdpyBCnYO8yzrVZOaesFvmW5VPJ08bm_oNJbkpwA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=c%E2%80%90MYC+expression+and+maturity+phenotypes+are+associated+with+outcome+benefit+from+addition+of+ixazomib+to+lenalidomide%E2%80%90dexamethasone+in+myeloma&rft.jtitle=European+journal+of+haematology&rft.au=Alessandra+Di+Bacco&rft.au=Bahlis%2C+Nizar+J&rft.au=Munshi%2C+Nikhil+C&rft.au=Herv%C3%A9+Avet%E2%80%90Loiseau&rft.date=2020-07-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0902-4441&rft.eissn=1600-0609&rft.volume=105&rft.issue=1&rft.spage=35&rft.epage=46&rft_id=info:doi/10.1111%2Fejh.13405&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0902-4441&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0902-4441&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0902-4441&client=summon |